XSENSIO SA

Their core work

XSENSIO SA is a Swiss deep-tech SME developing wearable biosensor platforms that continuously monitor disease biomarkers in sweat — without needles, blood draws, or clinical-lab infrastructure. Their core technology combines lab-on-chip miniaturization with skin-contact sensing to turn perspiration into a real-time diagnostic stream. The company has applied this platform to two distinct clinical needs: improving monitoring quality in clinical trials and tracking inflammation in at-risk patients for personalized care. Their products sit at the intersection of medical diagnostics, wearable electronics, and mHealth software, targeting both the clinical research market and point-of-care patient management.

What they specialise in

How they've shifted over time

XSENSIO's trajectory follows a textbook SME instrument arc: the 2018 Lab-on-Skin grant was a feasibility phase (SME-1, €50K) with no published keywords, functioning as proof-of-concept validation for the core sensing idea. By 2020, they had advanced to a full SME-2 commercialization project (CytoTrack, €1.75M) with a precise clinical focus — inflammation biomarkers in sweat for personalized care of at-risk patients. The keyword set that emerges in the second phase (sweat biomarkers, lab-on-chip, mHealth, complementary diagnostics, COVID-19) shows both technical maturation and market sharpening: the company moved from a generic wearable monitoring concept to a specific diagnostic use case with named clinical populations and disease context.

XSENSIO is moving from broad wearable sensing toward a defined clinical niche — continuous, non-invasive inflammation monitoring for chronic or high-risk patients — which positions them as a potential OEM sensing layer for digital therapeutics platforms, hospital-at-home programs, or pharma companion diagnostics.

How they like to work

XSENSIO has functioned exclusively as a solo coordinator in both H2020 projects, which is entirely consistent with the SME Instrument funding scheme — these grants are designed for single companies developing their own products, not consortia. This means their H2020 record reveals nothing about their appetite or skill for multi-partner collaboration; that dimension of their profile is simply unmeasured by this dataset. Organizations considering them as consortium partners should treat them as an untested quantity in that role, but their ability to lead and execute two back-to-back funded projects independently demonstrates strong internal project management.

XSENSIO's H2020 record shows zero external consortium partners, as both projects were solo SME Instrument grants — a funding mechanism that does not require partner organizations. Their real collaboration network (clinical validation sites, university research partners, hospital trial centers) is not visible through CORDIS data alone.

What sets them apart

XSENSIO occupies a narrow but commercially valuable niche: they are building the sensor hardware and data layer for sweat-based biomarker diagnostics, a space most diagnostics companies have avoided because of the technical difficulty of accurate electrochemical detection in a variable biological matrix like sweat. Based in Lausanne — within the EPFL ecosystem — they likely combine strong academic sensor science with commercial product development discipline. For a consortium needing a wearable sensing component with validated clinical trial applications, they offer a ready-made technology platform rather than a research prototype.

Highlights from their portfolio

• CytoTrack
  The largest investment in XSENSIO's portfolio at €1.75M (SME-2), this project represents their full commercialization push — a wearable inflammation tracker targeting at-risk patients with named COVID-19 relevance, running 2020–2024.
• Lab-on-Skin
  A lean €50K feasibility grant that established the company's core concept — skin-contact lab-on-chip for clinical monitoring — and seeded the technology validated in CytoTrack.